Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
Clinical trial NCT06341894 · RECRUITING
Trial details
- NCT number
- NCT06341894
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-17
- Primary completion
- 2027-06-01
- Enrollment
- 1163
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.